Human Asialoglycoprotein Receptor 1 Extracellular Domain (recombinant)
The Californer/10282007

SAN DIEGO - Californer -- Human Asialoglycoprotein Receptor 1 Extracellular Domain (recombinant)

Human Asialoglycoprotein Receptor 1 Extracellular Domain (recombinant) is a high quality protein that is produced using genetic engineering techniques. This protein is a part of the human asialoglycoprotein receptor 1, which is a cell surface receptor involved in the recognition and clearance of glycoproteins from the bloodstream. The extracellular domain of this receptor is the part of the protein that is located outside of the cell and is responsible for binding to specific ligands. This product has been used as a molecular tool for various biochemical applications. It has also been used in a wide array of other chemical and immunological applications. Custom bulk amounts of this product are available upon request.

Human Asialoglycoprotein Receptor 1 Extracellular Domain (recombinant)
Catalog number: B2016799
Lot number: Batch Dependent

More on The Californer

• Milwaukee Job Corps Center Hosts Alumni Day, Calls Alumni to Action on Open Enrollment Campaign
• Connect Promotes Dr. Petra Stegmann as Head of Entrepreneurial Programs
• Xonicwave Expands Premier IT & Cybersecurity Services to San Diego Businesses
• Clean Comedy Kings Debuts At Black Oak Casino Saturday January 3rd
• Golden Paper Identifies Global Growth in Packaging Papers and Upgrades Its High-End Production Capacity

Expiration Date: Batch dependent
Amount: 50 µg
Molecular Weight or Concentration: 28.8 kDa
Supplied as: Solution
Applications: a molecular tool for various biochemical applications
Storage: -80°C
Keywords: ASGPR1, ASGR1, C-type Lectin Domain Family 4 Member H1, CLEC4H1, Hepatic Lectin H1
Grade: Biotechnology grade. All products are highly pure. All solutions are made with Type I ultrapure water (resistivity >18 MΩ-cm) and are filtered through 0.22 um.

References:
1: Wymann S, Mischnik M, Leong D, Ghosh S, Tan X, Cao H, Kuehnemuth B, Powers GA, Halder P, de Souza MJ, James HS, Tomasetig V, Lind H, Rossato P, Owczarek CM, Ow SY, Dower SK, Baz Morelli A, Rowe T, Hardy MP. Sialylation-dependent pharmacokinetics and differential complement pathway inhibition are hallmarks of CR1 activity in vivo Biochem J. 2022 May 13;479(9):1007-1030.

https://moleculardepot.com/product/human-asialoglycoprotein-receptor-1-extracellular-domain-recombinant/